Low-cost generation of clinical-grade layperson-friendly pharmacogenetic passports using oligonucleotide arrays - Lanting, Pauline; Warmerdam, Robert; Slager, Jelle; Brugge, Harm; Ochi, Taichi; Benjamins, Marloes; Lopera-Maya, Esteban; Jankipersadsing, Soesma; Gelderloos-Arends, Jody; Teuben, Daphne; Hendriksen, Dennis; Charbon, Bart; et al. (medRxiv, 2024)
Pharmacogenomic (PGx) information is essential for precision medicine, enabling drug prescriptions to be personalized according to an individual’s genetic background. Almost all individuals will carry a genetic marker that affects their drug response, so the ideal drug prescription for these individuals will differ from the population-level guidelines. Currently, PGx information is often not available at first prescription, reducing its effectiveness. Pharmacogenetic information is most often obtained using special assays, making it expensive and time-consuming to generate. We therefore hypothesized that we could also use genome-wide oligonucleotide genotyping arrays to generate comprehensive PGx information (PGx passports), thereby decreasing the cost and time required for PGx testing, and lowering the barrier to generating PGx information prior to first prescription.Taking advantage of existing genetic data generated in two biobanks, we developed and validated Asterix, a low-cost clinical-grade PGx passport pipeline for 12 PGx genes. In these biobanks we performed and clinically validated genetic variant calling and statistical phasing and imputation. In addition, we developed and validated a novel CYP2D6 copy number variant calling tool, foregoing the need to use separate PCR-based copy number detection. Ultimately, we returned 1227 PGx passports to biobank participants via a layperson-friendly app, improving knowledge of PGx among citizens. Our study demonstrates the feasibility of a low-cost clinical-grade PGx passport pipeline that could be readily implemented in clinical settings to enhance personalized healthcare, ensuring that patients receive the most effective and safe drug therapy based on their unique genetic makeup.Competing Interest StatementNdBV and DTo are members of the Dutch Pharmacogenetics Working Group (DPWG). All other authors report no conflict of interest.Funding StatementThis work was supported by SNN (Samenwerkingsverband Noord Nederland) [OPSNN0229 PCH Ecosysteem WP4.4]; by Lifelines NEXT, which has been made possible by funds from a grant from the UMCG Hereditary Metabolic Diseases Fund; by the grants awarded to A.Z. (Netherlands Organization for Scientific Research [NWO] VIDI Grant [016.178.056], a European Research Council [ERC] starting grant [ERC-715772], and Gravitation program EXPOSOME-NL (NWO grant number 024.004.017)), and the Lifelines Biobank initiative, which has been made possible by funds from FES (Fonds Economische Structuurversterking), SNN and REP (Ruimtelijk Economisch Programma). L.F. is supported by grants from NWO [ZonMW-VIDI 917.14.374, ZonMW-VICI 09150182010019], by an ERC Starting grant [637640 ImmRisk] and through a Senior Investigator grant from the Oncode Institute. P.D. is funded by The Netherlands Organisation for Health Research and Development (ZonMw) [VENI 09150161910057]. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Medical Ethics Review Board of University Medical Center Groningen gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes